Lobectomy After Induction Therapy for NSCLC in the Presence of Persistent N2 Disease
Author:
Daly Benedict D. T.
Publisher
Springer London
Reference23 articles.
1. Veermachaneni NK, Feins RH, Stephenson BJ, Edwards LJ, Fernandez FG. Management of stage IIIA non-small cell lung cancer by thoracic surgeons in North America. Ann Thorac Surg. 2012;94:922–6.
2. Albain KS, Rusch VW, Crowley JJ, Rice TW, Turrisi AT, Weick JK, et al. Concurrent Cisplatin/Etoposide plus chest radiotherapy followed by surgery for stages IIIA (N2) and IIIB non-small cell lung cancer: mature results of Southwest Oncology Group phase II study 8805. J Clin Oncol. 1995;13:18880–92.
3. Mathisen DJ, Wain JC, Wright C, Choi N, Carey R, Hilgenberg A, et al. Assessment of preoperative accelerated radiotherapy and chemotherapy in stage IIIA (N2) non-small cell lung cancer. J Thorac Cardiovasc Surg. 1996;111:123–31.
4. Bueno R, Richards WG, Swanson SJ, Jaklitsch MT, Mentzer SJ, Sugarbaker DJ. Nodal stage after induction therapy for stage IIIA lung cancer determines patient survival. Ann Thorac Surg. 2000;70:1826–31.
5. Betticher DC, Schmitz SH, Totsch M, Hansen E, Joss C, von Briel C, et al. Mediastinal lymph node clearance after Docetaxel-Cisplatin neoadjuvant chemotherapy is prognostic of survival in patients with stage IIIA pN2 non-small cell lung cancer; a multicenter phase II trial. J Clin Oncol. 2003;21:1752–9.